Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ACLY | P53396 | 2/20 | 0.31 |
| ▸ | KIF11 | P52732 | 2/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24123999 | 0.88 | HTR2C (0.44) | GABRA1 | |
| SCHEMBL24123874 | 0.86 | LSS (0.42) | POLB | |
| SCHEMBL1659020 | 0.80 | NOTUM (0.46) | GABRB2ACLYNOTUM | |
| SCHEMBL1662047 | 0.80 | TSHR (0.41) | POLB | |
| SCHEMBL15561902 | 0.78 | TSHR (0.47) | POLB | |
| SCHEMBL24130965 | 0.76 | NOTUM (0.33) | GABRA1GABRB2KIF11NOTUMPOLB | |
| SCHEMBL16960033 | 0.76 | NOTUM (0.33) | GABRA1GABRB2NOTUMPOLB | |
| SCHEMBL10183607 | 0.75 | GABRA1 (0.52) | GABRA1GABRB2ACLYPOLB | |
| SCHEMBL803437 | 0.75 | TSHR (0.50) | GABRA1GABRB2ACLYPOLB | |
| SCHEMBL15516386 | 0.73 | NOTUM (0.41) | GABRB2ACLYNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | GABRA1 3469/4885GABRB2 4210/4885ACLY 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.